Raymond James Trust N.A. Cuts Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Raymond James Trust N.A. decreased its position in shares of Repligen Co. (NASDAQ:RGENFree Report) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,997 shares of the biotechnology company’s stock after selling 58 shares during the period. Raymond James Trust N.A.’s holdings in Repligen were worth $359,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Fortis Capital Advisors LLC purchased a new position in shares of Repligen in the 4th quarter worth $35,000. Park Place Capital Corp grew its position in Repligen by 90.2% in the third quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 120 shares in the last quarter. Signaturefd LLC increased its stake in Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 86 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in Repligen during the third quarter valued at approximately $51,000. Finally, UniSuper Management Pty Ltd purchased a new position in shares of Repligen in the 2nd quarter worth approximately $57,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN opened at $184.88 on Tuesday. The stock has a fifty day moving average price of $193.98 and a 200-day moving average price of $171.59. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The firm has a market cap of $10.31 billion, a PE ratio of 256.78, a P/E/G ratio of 6.48 and a beta of 1.03.

Repligen (NASDAQ:RGENGet Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The firm had revenue of $155.74 million during the quarter, compared to analyst estimates of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. Repligen’s revenue was down 16.6% on a year-over-year basis. During the same period last year, the firm posted $0.68 EPS. Equities research analysts predict that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Transactions at Repligen

In other Repligen news, COO James Bylund sold 4,373 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the transaction, the chief operating officer now directly owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP Ralf Kuriyel sold 3,517 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO James Bylund sold 4,373 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock worth $5,039,532 over the last quarter. 1.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on RGEN shares. KeyCorp lifted their price target on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. Stifel Nicolaus upped their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Finally, Benchmark cut shares of Repligen from a “buy” rating to a “hold” rating in a research report on Monday, December 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $196.70.

Read Our Latest Research Report on RGEN

Repligen Company Profile

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENFree Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.